V. ÖZKOCAMAN Et Al. , "Oral Valganciclovir As Preemptive Therapy for Cytomegalovirus Infection in Allogeneic Hematopoietic Stem Cell Transplant Recipients," BLOOD , vol.124, no.21, 2014
ÖZKOCAMAN, V. Et Al. 2014. Oral Valganciclovir As Preemptive Therapy for Cytomegalovirus Infection in Allogeneic Hematopoietic Stem Cell Transplant Recipients. BLOOD , vol.124, no.21 .
ÖZKOCAMAN, V., ÖZKALEMKAŞ, F., ALİ, R., Karacan, Y., Ersal, T., Gozden, H. E., ... Erus, T.(2014). Oral Valganciclovir As Preemptive Therapy for Cytomegalovirus Infection in Allogeneic Hematopoietic Stem Cell Transplant Recipients. BLOOD , vol.124, no.21.
ÖZKOCAMAN, VİLDAN Et Al. "Oral Valganciclovir As Preemptive Therapy for Cytomegalovirus Infection in Allogeneic Hematopoietic Stem Cell Transplant Recipients," BLOOD , vol.124, no.21, 2014
ÖZKOCAMAN, VİLDAN Et Al. "Oral Valganciclovir As Preemptive Therapy for Cytomegalovirus Infection in Allogeneic Hematopoietic Stem Cell Transplant Recipients." BLOOD , vol.124, no.21, 2014
ÖZKOCAMAN, V. Et Al. (2014) . "Oral Valganciclovir As Preemptive Therapy for Cytomegalovirus Infection in Allogeneic Hematopoietic Stem Cell Transplant Recipients." BLOOD , vol.124, no.21.
@article{article, author={VİLDAN ÖZKOCAMAN Et Al. }, title={Oral Valganciclovir As Preemptive Therapy for Cytomegalovirus Infection in Allogeneic Hematopoietic Stem Cell Transplant Recipients}, journal={BLOOD}, year=2014}